CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. (March 2012)

• Record Type: Journal Article
• Authors: Ciccolini, Joseph; Evrard, Alexandre; M''Batchi, Lithaty; Pourroy, Bertrand; Mercier, Cédric; Iliadis, Athanassios; Lacarelle, Bruno; Verschuur, Arnaud; Ouafik, L''Houcine; André, Nicolas
• Is Part Of: Pharmacogenomics. Volume 13:Number 4(2012)
• Page Start: 393
• Page End: 397
• Publication Date: 2012-03
• Subjects: children -- cytarabine -- cytidine deaminase -- non-Hodgkin lymphoma -- pharmacogenetics -- toxicity; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.11.175
• Languages: English
• ISSNs: 1462-2416

Abstract

We describe here the case of a 7-year old girl with lymphoma who developed life-threatening toxicities upon cytarabine plus mercaptopurine. Surprisingly, initial investigations on canonical thiopurine methyltransferase genetic polymorphism proved to be negative. We focused next on deregulations affecting the CDA gene implicated in the liver disposition of cytarabine. This patient was homozygous for both the 79A>C and the -31delC polymorphisms on the CDA gene and promoter, two genotypes with reported opposite effects on CDA phenotype. To determine the CDA status of this patient, additional functional testing was performed and eventually demonstrated that this patient was a poor metabolizer. This case demonstrates that besides affecting thiopurine methyltransferase, dysregulations with CDA should be screened to anticipate toxicities with the cytarabine plus mercaptopurine combination.